Ticker Details
AbCellera Biologics Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.04B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.35 | 3.10%
Avg Daily Range (30 D):	$0.08 | 2.45%
Avg Daily Range (90 D):	$0.11 | 2.97%

Institutional Daily Volume
Avg Daily Volume:	2.42M
Avg Daily Volume (30 D):	2.76M
Avg Daily Volume (90 D):	3.49M

Trade Size
Avg Trade Size (Sh.):	168
Avg Trade Size (Sh.) (30 D):	197
Avg Trade Size (Sh.) (90 D):	222

Institutional Trades
Total Institutional Trades:	1,334
Avg Institutional Trade:	$1.77M
Avg Institutional Trade (30 D):	$1.64M
Avg Institutional Trade (90 D):	$.97M
Avg Institutional Trade Volume:	.17M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.93M
Avg Closing Trade (30 D):	$.79M
Avg Closing Trade (90 D):	$.7M
Avg Closing Volume:	199.32K

News

Aug 14, 2025 @ 11:23 AM Prelude Cuts Q2 Losses and Costs 13% Source: Jesterai

Jul 30, 2025 @ 5:00 PM Global Antibody Discovery Market to Observe Stupen... Source: Delveinsight

Jun 13, 2024 @ 9:40 AM Down 57%, Is AbCellera Biologics a Buy on the Dip?... Source: newsfeedback@fool.com (Cory Renauer)

May 8, 2024 @ 8:30 AM AbCellera Biologics (ABCL) Q1 2024 Earnings Call T... Source: newsfeedback@fool.com (Motley Fool Transcribing)

May 7, 2024 @ 10:05 PM AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, M... Source: Zacks Equity Research

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.49	$-.03	$-.49
Diluted EPS	$-.49	$-.03	$-.49
Revenue	$75.13M	$44.85M	$75.13M
Gross Profit
Net Income / Loss	$-146.41M	$-8.95M	$-146.41M
Operating Income / Loss	$-217.1M	$-28.58M	$-217.1M
Cost of Revenue
Net Cash Flow	$-28.37M	$44.8M	$-28.37M
PE Ratio